54
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Effect of farmorubicin both free and associated with poly(butylcyanoacrylate) nanoparticles on phagocytic and NK activity of peritoneal exudate cells from tumor-bearing mice

&
Pages 302-310 | Received 09 Aug 2006, Accepted 14 Mar 2007, Published online: 08 Oct 2008
 

Abstract

The effect of Epirubicin (farmorubicin, FR), either free or associated with poly(butylcyanoacrylate) nanoparticles (PBCN) upon the phagocytic and natural killer (NK) activity of peritoneal exudate cells (PECs) harvested from Lewis lung carcinoma (LLC)-bearing-mice was investigated. Phagocytic and NK activity were tested 72 and 96 h, respectively after the last four intraperitoneal (i.p.) injections of the tested compounds have been administered to the mice. Phagocytic activity was evaluated in vitro by phagocytic index and ingestion capacity using a phagocytic assay. NK activity was evaluated in a direct cytotoxic test, in which PECs were used as effector cells while human erythroleukemic K-562 cells were used as target cells. The phagocytic activity of PECs, harvested from tumor-bearing mice, was stimulated after treatment with FR free, FR associated with polymer nanoparticles and with unloaded PBCN. The NK activity of PECs was strongly stimulated by unloaded PBCN. FR both free and encapsulated into the polymer matrix during the polymerization of n-butylcyanoacrylate (n-BCA) stimulated the NK activity of PECs, while FR adsorbed onto nanoparticles restrained it. These results suggest that the association of FR with nanoparticles modifies selectively its immunomodulating ability without producing any significant immunological disturbances. The toxicity of some of FR polymer forms towards PECs, displaying NK activity, probably comes from the enhanced local drug concentration on the membrane surface of the immune cells. However, it is insufficient to preclude the use of nanoparticles as drug delivery system.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.